RxDoctor Payments Data

Pitayadet Jumrussirikul, MD

Clinical Cardiac Electrophysiology · West Des Moines, IANPI 1689656605

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $14,272 of the $23,079 with a category attached, or 61.8%. 9 manufacturers reported payments, led by Medtronic at 57.8% of the total. 2025 is the largest year on record at $9,730, 2.6 times the $3,780 reported in 2019.

$23,079in general payments, 2019–2025

Across 212 payments — averaging $108.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Abbott$7K
  • Boston Scientific$2K
  • Philips North America LLC$337
  • Atricure, Inc.$241
  • Edwards Lifesciences$37
  • plus $54 from 3 others
$98,607in research payments, 2019–2025

Across 23 payments — averaging $4287.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$96K
  • Boston Scientific$2K

What the payments were for

  • Travel & lodging$14,27262%
  • Food & beverage$8,80738%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,079 in reported general payments places this provider in the 60th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

See all clinical cardiac electrophysiology providers in Iowa

Medicare billing

Part B allowed, 2024
$257,195
Medicare patients
2,606
Services billed
5,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$259,253
XareltoRivaroxaban89$66,587
Diltiazem 24hr Er (Cd)Diltiazem Hcl89$3,263
Flecainide Acetate151$3,222
Amiodarone Hcl325$2,662
Metoprolol Succinate238$2,119
SotalolSotalol Hcl94$1,137
Propafenone Hcl17$1,115
Potassium Chloride43$456
Warfarin Sodium50$374
Pantoprazole Sodium68$285
Amlodipine Besylate48$263
Furosemide52$180
Metoprolol Tartrate28$173
Atorvastatin Calcium36$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$259,253345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

Other clinical cardiac electrophysiology in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →